1. Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+KLRG1−CD4+T cells
- Author
-
Bull, N. C., Stylianou, E., Kaveh, D. A., Pinpathomrat, N., Pasricha, J., Harrington-Kandt, R., Garcia-Pelayo, M. C., Hogarth, P. J., and McShane, H.
- Abstract
BCG, the only vaccine licensed against tuberculosis, demonstrates variable efficacy in humans. Recent preclinical studies highlight the potential for mucosal BCG vaccination to improve protection. Lung tissue-resident memory T cells reside within the parenchyma, potentially playing an important role in protective immunity to tuberculosis. We hypothesised that mucosal BCG vaccination may enhance generation of lung tissue-resident T cells, affording improved protection against Mycobacterium tuberculosis. In a mouse model, mucosal intranasal (IN) BCG vaccination conferred superior protection in the lungs compared to the systemic intradermal (ID) route. Intravascular staining allowed discrimination of lung tissue-resident CD4+T cells from those in the lung vasculature, revealing that mucosal vaccination resulted in an increased frequency of antigen-specific tissue-resident CD4+T cells compared to systemic vaccination. Tissue-resident CD4+T cells induced by mucosal BCG displayed enhanced proliferative capacity compared to lung vascular and splenic CD4+T cells. Only mucosal BCG induced antigen-specific tissue-resident T cells expressing a PD-1+KLRG1−cell-surface phenotype. These cells constitute a BCG-induced population which may be responsible for the enhanced protection observed with IN vaccination. We demonstrate that mucosal BCG vaccination significantly improves protection over systemic BCG and this correlates with a novel population of BCG-induced lung tissue-resident CD4+T cells.
- Published
- 2019
- Full Text
- View/download PDF